718-P: Long-Term Safety of Intranasal Insulin (INI) in Insulin-Dependent Type 2 Diabetes (T2DM-IDDM): A Safety Substudy of Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Trial
BECERRA L, MENDEZ B, KHAN F, MANTZOROS C, NOVAK P, LIOUTAS V, NGO L, NOVAK V, TREVINO J. 718-P: Long-Term Safety of Intranasal Insulin (INI) in Insulin-Dependent Type 2 Diabetes (T2DM-IDDM): A Safety Substudy of Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Trial. Diabetes 2021, 70 DOI: 10.2337/db21-718-p.Peer-Reviewed Original ResearchIntranasal insulinSerious adverse eventsCapillary glucoseSpouse/partnerContinuous glucose monitoringPlacebo groupAdverse eventsSubcutaneous insulinInsulin-dependent type 2 diabetesType 2 diabetes trialsLevel 1 hypoglycemiaPlacebo-treated participantsWeeks of treatmentFuture larger studiesType 2 diabetesLevel 2 hypoglycemiaNovo NordiskWorld Health OrganizationAdvisory PanelDiabetes (ACCORD) trialConcomitant administrationInsulin levelsKidney diseaseFunctional declineTerm safety